Nike's Q1 Confirms Prolonged Reset; Hold Until Revenue Quality Improves

What happened

Nike reported fiscal Q1 2027 revenue of $11.2 billion, down 4% year over year, as growth in performance categories and North America was offset by sharp declines in Greater China, Sportswear, and Jordan. Management now expects full-year FY27 revenue to decline at a high-single-digit rate with EBIT falling even faster, signaling that the recovery will take several more quarters. Gross margin improved 60 basis points to 42.8%, but the gain was driven by lower logistics costs and currency rather than cleaner pricing; average selling prices actually fell due to higher discounts and channel mix. The company extended its Greater China cleanup actions beyond fiscal 2027, and its new Pace cost program targets $2.5 billion in cumulative savings through 2031, confirming that structural fixes are now necessary. Meanwhile, competitor adidas is growing strongly in the same geographies and categories, underscoring that Nike's problems are company-specific rather than macro-driven.

Implication

Investors should treat Nike as a hold or tactical trim on rallies above $41, as the next two quarterly reports are critical tests of whether the turnaround is gaining traction. The balance sheet remains strong with $8.4 billion in liquidity and low leverage, limiting downside risk, but the stock is not cheap enough to buy aggressively given the lack of revenue quality inflection. A better entry point is near $30, where weaker FY27 assumptions are more fully discounted, while a high-conviction buy would require China declines to narrow sharply, Direct to flatten, and margin gains to come from lower markdowns. Monitor Q2 and Q3 FY27 results for improvement from Q1's Greater China wholesale decline of -31% and digital decline of -28%; failure to improve there would invalidate the recovery thesis. Until then, position sizes should remain small, and capital should be reallocated to peers with stronger current momentum, such as adidas.

Thesis delta

The new article aligns closely with the existing WAIT thesis, reinforcing the view that the business, not the brand, is impaired and that the turnaround remains prolonged. No material shift in valuation or outlook is warranted; the thesis maintains that the stock is fairly valued at current levels with limited margin of safety until revenue quality improves. Confidence in the WAIT rating is unchanged, and investors should continue to watch for inflection points in China and Direct channels over the next two quarters.